Follow
Nicholas J. Short
Nicholas J. Short
Associate Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center
Verified email at mdanderson.org
Title
Cited by
Cited by
Year
Acute myeloid leukaemia
NJ Short, ME Rytting, JE Cortes
The Lancet 392 (10147), 593-606, 2018
6562018
New Oral Anticoagulants and the Cancer Patient.
NJ Short, JM Connors
The Oncologist, 2013
2562013
Advances in the treatment of acute myeloid leukemia: new drugs and new challenges
NJ Short, M Konopleva, TM Kadia, G Borthakur, F Ravandi, CD DiNardo, ...
Cancer discovery 10 (4), 506-525, 2020
2522020
Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis
NJ Short, S Zhou, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ...
JAMA oncology 6 (12), 1890-1899, 2020
2452020
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ...
The Lancet Haematology 7 (10), e724-e736, 2020
2362020
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single …
E Jabbour, NJ Short, F Ravandi, X Huang, N Daver, CD DiNardo, ...
The Lancet Haematology 5 (12), e618-e627, 2018
2202018
Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia
NJ Short, E Jabbour, K Sasaki, K Patel, SM O’Brien, JE Cortes, R Garris, ...
Blood, The Journal of the American Society of Hematology 128 (4), 504-507, 2016
2202016
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase …
H Kantarjian, F Ravandi, NJ Short, X Huang, N Jain, K Sasaki, N Daver, ...
The Lancet Oncology 19 (2), 240-248, 2018
2122018
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia
CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ...
Journal of Clinical Oncology 39 (25), 2768, 2021
2002021
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN
E Jabbour, NJ Short, G Montalban-Bravo, X Huang, C Bueso-Ramos, ...
Blood, The Journal of the American Society of Hematology 130 (13), 1514-1522, 2017
1752017
Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: a propensity …
K Sasaki, EJ Jabbour, F Ravandi, NJ Short, DA Thomas, ...
Cancer 122 (23), 3650-3656, 2016
1752016
Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia
R Assi, H Kantarjian, NJ Short, N Daver, K Takahashi, G Garcia-Manero, ...
Clinical Lymphoma Myeloma and Leukemia 17 (12), 897-901, 2017
1482017
Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic …
E Jabbour, F Ravandi, P Kebriaei, X Huang, NJ Short, D Thomas, ...
JAMA oncology 4 (2), 230-234, 2018
1392018
Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
B Samra, E Jabbour, F Ravandi, H Kantarjian, NJ Short
Journal of hematology & oncology 13, 1-17, 2020
1362020
Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens
CA Lachowiez, S Loghavi, TM Kadia, N Daver, G Borthakur, ...
Blood advances 4 (7), 1311-1320, 2020
1262020
Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
NJ Short, H Kantarjian, F Ravandi, N Daver
Therapeutic Advances in Hematology 10, 2040620719827310, 2019
1142019
Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia
NJ Short, G Montalban-Bravo, H Hwang, J Ning, MJ Franquiz, ...
Blood advances 4 (22), 5681-5689, 2020
1122020
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: a consensus of North American experts
NJ Short, E Jabbour, M Albitar, M de Lima, L Gore, J Jorgensen, ...
American journal of hematology 94 (2), 257-265, 2019
1112019
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic …
TM Kadia, PK Reville, G Borthakur, M Yilmaz, S Kornblau, Y Alvarado, ...
The Lancet Haematology 8 (8), e552-e561, 2021
992021
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative …
E Jabbour, K Sasaki, F Ravandi, X Huang, NJ Short, M Khouri, P Kebriaei, ...
Cancer 124 (20), 4044-4055, 2018
992018
The system can't perform the operation now. Try again later.
Articles 1–20